Get the Stockscreener App
1,057.89
1.63%
-17.58
After Hours:
1057.51
-0.38
-0.04%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,057.89, with a volume of 3.07M.
It is down -1.63% in the last 24 hours and up +22.60% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,075.47
Open:
$1074.38
24h Volume:
3.07M
Relative Volume:
0.82
Market Cap:
$1.00T
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.32
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-1.15%
1M Performance:
+22.60%
6M Performance:
+43.41%
1Y Performance:
+33.01%
1-Day Range:
$1,055.00
$1,084.15
1-Week Range:
$1,055.00
$1,111.99
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,057.89 | 962.57B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.34 | 498.53B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.11 | 402.43B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
128.97 | 250.21B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.83 | 260.19B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Peptron tumbles after Eli Lilly extends technology evaluationCHOSUNBIZ - Chosun Biz
Eli Lilly stock price target raised to $1,286 by BofA on GLP1 franchise strength - Investing.com Canada
History Says These 7 S&P 500 Stocks Often Rally In December - Benzinga
Eli Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal - Investopedia
Eli Lilly Slashes Prices of Popular Weight-Loss Drug Zepbound - NTD News
Eli Lilly Reduces Cost of Zepbound Single-Dose Vials for Self-Pay Patients - geneonline.com
Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect - GuruFocus
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients - PharmExec.com
What Eli Lilly's move to cut prices on obesity drug Zepbound means for investors - CNBC
Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle - Fox Business
Eli Lilly Launches SURMOUNT-REAL UK Trial to Study Tirzepatide for Weight Management - geneonline.com
Lilly Launches UK Trial of Weight-Loss Drug as US Price Drops - PharmTech.com
Market Voices: Trump on Fed chair, US-UK pharma deal, Lilly's Zepbound - Seeking Alpha
Are GLP-1s The New Performance-Enhancing Drug For Careers? - Benzinga
Eli Lilly cuts cash price for Zepbound weight loss drug vials - qz.com
Lilly cuts prices on Zepbound vials sold on LillyDirect - Indianapolis Business Journal
Eli Lilly cuts Zepbound price to widen access for obesity drug - Reuters
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition - Proactive financial news
Eli Lilly slashes Zepbound vial prices on its direct-to-consumer platform - Sherwood News
Eli Lilly Stock in Focus After Slashing Cost of Popular Drug - Schaeffer's Investment Research
Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program - BioSpace
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - MSN
Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound - MarketScreener
Eli Lilly (LLY) Reduces Zepbound Prices on Direct Platform - GuruFocus
Eli Lilly slashes obesity drug price by up to 20% - Los Angeles Times
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook - ts2.tech
Weight-Loss Drug Zepbound Cost Drops To $299 A Month After Trump Deal - Forbes
Eli Lilly (LLY) Reduces Zepbound Prices Amid Rising Demand for O - GuruFocus
Eli Lilly lowers price of obesity drug - medwatch.com
Lilly drops price of Zepbound - PharmaLive
Eli Lilly lowers starting dose costs for Zepbound on direct purchase platform (LLY:NYSE) - Seeking Alpha
Eli Lilly stock holds Overweight rating at Cantor Fitzgerald on GLP-1 growth - Investing.com India
Eli Lilly cuts direct-sale price of Zepbound to widen access to treatment - MarketScreener
Eli Lilly cuts price for popular weight-loss drug Zepbound - USA Today
Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk - MSN
Eli Lilly reduces Zepbound prices on direct platform - StreetInsider
Eli Lilly (LLY) Sets Tender Offer to Acquire Adverum Biotechnolo - GuruFocus
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns By Investing.com - Investing.com South Africa
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly’s tender offer for Adverum nears deadline amid liquidity concerns - Investing.com
Eli Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers - Bloomberg.com
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly - Yahoo Finance
Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes It A Clear Hold (NYSE:LLY) - Seeking Alpha
How Analyst Views Are Shaping Eli Lilly’s Evolving Growth Story - Yahoo Finance UK
Eli Lilly Becomes First Trillion-Dollar Health Company - Optometry Advisor
Eli Lilly (LLY): Evaluating Valuation as Mounjaro and Zepbound Fuel Growth and Policy Expands Access - simplywall.st
Eli Lilly’s Swiss Trading Update: Examining the Metrics - Meyka
Eli Lilly to Set up Manufacturing Base for Mounjaro in Korea in Partnership with SK Inc. - Businesskorea
Eli Lilly News Today, Nov 30: Significant Volume Surge Signals Market Interest - Meyka
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock - ts2.tech
Jim Cramer Says Eli Lilly “May Have the Greatest Drug Franchise of All Time” With GLP-1 and Diabetes Medication - Insider Monkey
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):